Slide 1: Year-End Fiscal 2025 Shareholder Update Call
Year-End Fiscal 2025 Shareholder Update Call 1 Full Year 2025 Financial Results
Slide 2: Safe Harbor
Safe Harbor The matters discussed in this presentation include forward-looking statements about the business prospects of IGC Pharma, Inc. Forward-looking statements are often preceded by words such as believes, expects, anticipates, plans, will, goal, may, intends, assumes, or similar expressions.
Slide 3: Overview
Overview IGC Pharma develops therapies for Alzheimer’s disease (AD) and other chronic conditions. Lead asset IGC-AD1 in Phase 2 trials for agitation in Alzheimer’s dementia; also advancing toward trials as a potential disease-modifying therapy AI integrated R&D platform accelerating drug discovery,
Slide 4: Operational Highlights – FY 2025 at a Glance
Operational Highlights – FY 2025 at a Glance Phase 2 CALMA Trial Progress Interim data showed reduced agitation, improved sleep, and cognitive benefit CALMA Trial Expansion We have 22 sites under contract, including leading institutions in the U.S. and Canada Advancing IGC-AD1 as a Disease-Modifying
Slide 5: Phase 2 CALMA Trial Progress
Phase 2 CALMA Trial Progress 5 Year-End Fiscal 2025 Full Shareholder Year Update 2025 Financial Call Results
Slide 6: Agitation in Alzheimer's Dementia
Agitation in Alzheimer’s Dementia Impacts up to 76% of 50 million Alzheimer’s patients worldwide, and 7 million Alzheimer’s patients in the U.S. A group of hard to manage behaviors that include physical or verbal aggression, wandering, pacing, excessive motor movements, among others Leads to long te
Slide 7: CALMA Trial Overview
CALMA Trial Overview Multicenter, Double Blind, Randomized, Placebo- Controlled Trial Objectives: Evaluate the safety and efficacy of IGC-AD1 on agitation in AD at week 6 (EOT) and separately at week 2 Key Inclusion Criteria: Diagnosis of probable AD using the NIA-AA criteria The study targets Clini
Slide 8: CALMA Trial Expansion
CALMA Trial Expansion. Active Meta Campaign Sites as of FY 2024: Added FY 2025: Added subsequent to FY 2025: 8 Year-End Fiscal 2025 Shareholder Update Call
Slide 9: Phase 2 Interim Results Indicate Drug Could Outperform Current Approved Therapy
Phase 2 Interim Results Indicate Drug Could Outperform Current Approved Therapy2 IGC-AD1 CMAI Score by Week 6 CMAI score: Cohen-Mansfield Agitation compared to Brexpiprazole trial results Inventory, a clinical tool used to assess and quantify agitation levels In this study, patients who took IGC-AD1
Slide 10: IGC-AD1 Demonstrates Potential as a Disease-Modifying Therapy
IGC-AD1 Demonstrates Potential as a Disease-Modifying Therapy The combination of APIs in IGC-AD1 preserves Aβ40 Monomers and IGC-AD1 reduces ptau/tau Inhibits Aggregation as Assessed by ThT and GSK3~ reduces Assay which may contribute to lowering tangles amyloid burden in Alzheimer’s disease 10 Year
Slide 11: Summary: Preclinical Data
Summary: Preclinical Data IGC-AD1: Preclinical Evidence Supporting Disease-Modifying Potential in Humans Decreases Aβ₄₀ production and aggregation Improves spatial memory in APP/PS1 mice, in cell models, implicates amyloid pathway correlating with potential cognitive benefit in modulation. 1 human A
Slide 12: IGC-AD1 Phase 2 Strategy: Agitation in AD
IGC-AD1 Phase 2 Strategy: Agitation in AD Preclinical studies demonstrated disease modifying potential, including reduction in pTau, Aβ aggregation, and mitochondrial dysfunction. Phase 1 clinical data showed clinical and statistically significant improvements in results agitation symptoms in patien
Slide 13: New AI Diagnostic Platform
New AI Diagnostic Platform 13 Year-End Fiscal 2025 Full Shareholder Year Update 2025 Financial Call Results
Slide 14: Foundation model for Alzheimer's: MINT-AD
Foundation model for Alzheimer’s: MINT-AD MINT-AD (Multi-modal Interpretable Transformer for Alzheimer's disease) MINT-AD has three aims: 1. Identify groups of risk factors for Alzheimer’s disease 2. Predict cognitive decline 2 to 5 years in advance 3. Deploy MINT-AD with doctors as a tool to help d
Slide 15: FY 2025 AI-Achievements
FY 2025 AI-Achievements Recognized by NIH for Innovation - Selected as a Top 15 finalist in NIA’s PREPARE Challenge for early Alzheimer’s detection Beta version of MINT-AD integrating imaging, cognitive, genetic, and clinical data to improve accuracy in detecting and differentiating dementia types A
Slide 16: Pipeline Expansion
Pipeline Expansion Asset Preclinical Phase I Phase II Phase III Milestones Interim Phase 2 IGC-AD1 Targets NPS and AD pathology data available Bio Equivalence to LMP-platform Targets NPS and AD pathology IGC-AD1 2025 TGR-platform Targets Aβ plaques (Early- Moderate AD) Tox study 2025 IGCM-platform T
Slide 17: Strategic Expansion into Metabolic Disorders
Strategic Expansion into Metabolic Disorders Expansion into GLP-1 therapies targets multi-billion-dollar global market for weight management and type-2 diabetes treatments Research indicates potential synergies between GLP1r neuroprotection and metabolic regulation via GLP-1 mechanisms CB1r Diversif
Slide 18: Financial Summary
Financial Summary 1. Focused on minimizing dilution and maintaining a clean cap table 2. Renewed $12 million line of credit 3. Funding business through selective capital raises 4. Focusing capital deployment on efficiently advancing drugs through clinic at a low cost per patient 5. Multiple pending
Slide 19: Upcoming Milestones
Upcoming Milestones 1. Initiate IND-enabling studies for expanded pipeline in 2025 2. Complete Phase 2 trial as a treatment for Agitation in AD 3. Expand IGC-AD1 as a disease- modifying treatment with Phase 2 trial targeted for late 2025 19 Year-End Fiscal 2025 Shareholder Update Call
Slide 20: Q&A THANK YOU.
Q&A THANK YOU. Year-End Fiscal 2025 Shareholder Update Call 20 Full Year 2025 Financial Results